Featured Publications
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2021
Safety and efficacy outcomes of the Pioneer Plus catheter in endovascular revascularization of lower extremity chronic total occlusions
Sheikh AB, Llanos-Chea F, Jelani QU, Anantha-Narayanan M, Attaran R, Schneider M, Ionescu C, Regan C, Nagpal S, Smolderen KG, Mena-Hurtado C. Safety and efficacy outcomes of the Pioneer Plus catheter in endovascular revascularization of lower extremity chronic total occlusions. Journal Of Vascular Surgery 2021, 74: 746-755. PMID: 33592298, DOI: 10.1016/j.jvs.2021.01.045.Peer-Reviewed Original ResearchConceptsMajor adverse limb eventsAdverse limb eventsDevice-related complicationsProcedure-related complicationsProcedure-related outcomesProcedural successEfficacy outcomesPseudoaneurysm formationSafety outcomesLimb eventsLower extremity chronic total occlusionMajor adverse cardiovascular eventsChronic total occlusion interventionAccess site hematomaAcute arterial thrombosisAcute limb ischemiaAdverse cardiovascular eventsProvider-level factorsArteriovenous fistula formationHigh-volume centersChronic total occlusionMajor bleedingPreprocedural symptomsCardiovascular eventsCatheter use
2020
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease
Kim TI, Kiwan G, Mohamedali A, Zhang Y, Mena-Hurtado C, Mojibian H, Guzman RJ, Ochoa Chaar CI. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. Journal Of Vascular Surgery 2020, 73: 911-917. PMID: 33038480, DOI: 10.1016/j.jvs.2020.08.146.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsEndovascular ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProsthesis DesignRetreatmentRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular PatencyConceptsPaclitaxel-coated devicesPeripheral artery diseaseCause of mortalityPCD useRisk of mortalityCumulative doseFemoropopliteal peripheral artery diseaseKaplan-Meier survival curvesLong-term mortalityPeripheral arterial diseaseCox regression analysisDrug-coated balloonsOutcome of treatmentDrug-eluting stentsMajor amputationPrimary patencyReintervention rateArtery diseaseArterial diseaseRandomized trialsOpen surgeryPresent studySingle institutionEndovascular interventionPatientsUtility of Intravascular Ultrasound in Peripheral Vascular Interventions: Systematic Review and Meta-Analysis
Sheikh AB, Anantha-Narayanan M, Smolderen KG, Jelani QU, Nagpal S, Schneider M, Llanos F, Ionescu C, Regan C, Attaran R, Altin SE, Mena-Hurtado C. Utility of Intravascular Ultrasound in Peripheral Vascular Interventions: Systematic Review and Meta-Analysis. Vascular And Endovascular Surgery 2020, 54: 413-422. PMID: 32338163, DOI: 10.1177/1538574420920998.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsPeriprocedural adverse eventsVascular complicationsAdverse eventsIntravascular ultrasoundPrimary patencyCause mortalityTechnical successMyocardial infarctionObservational studyVascular interventionsEnd pointSimilar patency ratesSimilar primary patencyPrimary end pointRate of reinterventionSecondary end pointsPeripheral arterial diseaseImproved clinical outcomesIVUS groupAmputation rateArterial diseaseClinical outcomesPatency ratesLower risk
2019
Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion
Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, Lansky A. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2019, 7: 527-534. PMID: 31203859, DOI: 10.1016/j.jvsv.2019.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsEndovascular ProceduresFemaleHumansIliac VeinMaleMay-Thurner SyndromeMiddle AgedPlatelet Aggregation InhibitorsPostthrombotic SyndromeProsthesis DesignRecurrenceRetrospective StudiesStentsTime FactorsTreatment OutcomeVascular PatencyVena Cava, InferiorVenous ThrombosisConceptsAcute deep vein thrombosisPost-thrombotic syndromeDeep vein thrombosisMay-Thurner syndromeDuration of anticoagulationAntiplatelet therapyPatency ratesIliocaval stentingIpsilateral deep vein thrombosisIliocaval venous stentingPrimary patency rateStent patency ratesCommon femoral veinVariety of indicationsLarge teaching hospitalVein thrombosisVenous stentingRetrospective reviewDVT groupStent groupFemoral veinProcedural dataStent patencyStent occlusionTeaching hospitalDrug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputationManagement of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature
Halpin D, Erben Y, Jayasuriya S, Cua B, Jhamnani S, Mena-Hurtado C. Management of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature. Vascular And Endovascular Surgery 2017, 51: 220-227. PMID: 28376704, DOI: 10.1177/1538574417702773.Peer-Reviewed Original ResearchConceptsCommon femoral endarterectomyTarget lesion revascularizationCommon femoral arteryCFA stenosisEndovascular therapyEndovascular studiesPrimary patencyAtherosclerotic stenosisTechnical successEndovascular interventionFemoral arteryGood short-term patencyFurther trial dataFirst-line therapyPercentage of patientsCritical limb ischemiaStandard of careNumber of patientsShort-term patencyLower ratesHigh rateEndovascular literatureFemoropopliteal systemLesion revascularizationLimb ischemia
2016
A Unique Case of May-Thurner Syndrome Extrinsic Compression of the Common Iliac Vein After Iliac Artery Stenting
Hermany PL, Badheka AO, Mena-Hurtado CI, Attaran RR. A Unique Case of May-Thurner Syndrome Extrinsic Compression of the Common Iliac Vein After Iliac Artery Stenting. JACC Cardiovascular Interventions 2016, 9: e39-e41. PMID: 26896887, DOI: 10.1016/j.jcin.2015.11.042.Peer-Reviewed Original Research
2015
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. New England Journal Of Medicine 2015, 373: 145-153. PMID: 26106946, DOI: 10.1056/nejmoa1406235.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsPaclitaxel-coated balloonPeripheral artery diseasePercutaneous transluminal angioplastyPrimary patencyArtery diseaseTransluminal angioplastyStandard angioplastyStandard balloonSymptomatic femoropopliteal peripheral artery diseaseFemoropopliteal peripheral artery diseasePrimary efficacy end pointPrimary safety end pointEnd pointSignificant between-group differencesComposite of freedomPrimary safety eventsSymptomatic intermittent claudicationEfficacy end pointSafety end pointFemoropopliteal artery diseaseProportion of patientsSignificant atherosclerotic lesionsBetween-group differencesRate of death
2014
Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C, Investigators E. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovascular Interventions 2014, 8: 92-101. PMID: 25499305, DOI: 10.1016/j.jcin.2014.09.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlloysAmputation, SurgicalAngioplasty, BalloonAtherectomyChronic DiseaseCombined Modality TherapyConstriction, PathologicFemaleFemoral ArteryHumansLaser TherapyLasers, ExcimerLimb SalvageMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesProsthesis DesignRecurrenceStentsTime FactorsTreatment OutcomeUnited StatesVascular PatencyConceptsPercutaneous transluminal angioplastyTarget lesion revascularizationExcimer laser atherectomyLaser atherectomyAdjunctive percutaneous transluminal angioplastyMajor adverse event rateChronic peripheral artery diseaseLesion lengthLifestyle-limiting claudicationPrimary safety endpointRutherford class 1Target lesion lengthPrimary efficacy endpointMajor adverse eventsPeripheral artery diseaseAdverse event ratesCritical limb ischemiaFemoropopliteal ISRLesion revascularizationEfficacy endpointSafety endpointAdverse eventsLimb ischemiaTransluminal angioplastyArtery disease